These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 23432662

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L, Bahij El-Houri R.
    Molecules; 2018 Sep 22; 23(10):. PubMed ID: 30248999
    [Abstract] [Full Text] [Related]

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 4. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.
    Mol Pharmacol; 2012 Jul 14; 82(1):68-79. PubMed ID: 22496518
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.
    J Pharmacol Exp Ther; 2006 Aug 14; 318(2):863-71. PubMed ID: 16682454
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 14; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 9. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
    Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.
    Biochem Pharmacol; 2006 Aug 14; 72(4):446-54. PubMed ID: 16797489
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The DLK gene is a transcriptional target of PPARγ.
    Couture JP, Blouin R.
    Biochem J; 2011 Aug 15; 438(1):93-101. PubMed ID: 21585338
    [Abstract] [Full Text] [Related]

  • 12. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.
    J Med Chem; 2011 Dec 22; 54(24):8541-54. PubMed ID: 22070604
    [Abstract] [Full Text] [Related]

  • 13. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, Choi HH, Hur Y, Kim E, Park YH, Park CS, Kim JG, Lim JI, Shin CY.
    Eur J Pharmacol; 2011 Jan 15; 650(2-3):673-81. PubMed ID: 20974124
    [Abstract] [Full Text] [Related]

  • 14. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Almanza-Pérez JC, Román-Ramos R, Alarcón-Aguilar FJ, Hernández-Rosado JV, Moreno-Díaz H, Díaz-Coutiño D, Navarrete-Vázquez G.
    Chem Biol Drug Des; 2013 Apr 15; 81(4):474-83. PubMed ID: 23289972
    [Abstract] [Full Text] [Related]

  • 15. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
    Milton FA, Cvoro A, Amato AA, Sieglaff DH, Filgueira CS, Arumanayagam AS, de Lima Mdo C, Pitta IR, de Assis Rocha Neves F, Webb P.
    Biochem Biophys Res Commun; 2015 Aug 28; 464(3):718-23. PubMed ID: 26168725
    [Abstract] [Full Text] [Related]

  • 16. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA.
    Diabetes; 2006 Sep 28; 55(9):2523-33. PubMed ID: 16936200
    [Abstract] [Full Text] [Related]

  • 17. INT131: a selective modulator of PPAR gamma.
    Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DH, Jaen J, Walker NP, Learned RM, Chen JL, Li Y.
    J Mol Biol; 2009 Mar 13; 386(5):1301-11. PubMed ID: 19452630
    [Abstract] [Full Text] [Related]

  • 18. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X, Zhou X, Chen W, Long L, Li W, Yang X, Li S, Wang L.
    Biochim Biophys Acta; 2015 Jan 13; 1850(1):62-72. PubMed ID: 25305559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.
    J Biol Chem; 2008 Apr 04; 283(14):9168-76. PubMed ID: 18263587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.